Every material Form 8-K ANI Pharmaceuticals filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ANI Pharmaceuticals entered a 364-day senior bridge credit facility of up to $676 million with JPMorgan Chase Bank, N.A. as administrative agent. The facility will be used to finance its recommended public cash offer for Egetis Therapeutics shares, convertible loan and warrants, valued at about SEK 5.6 billion, or approximately $559.9 million, and to refinance ANI's existing term loans and some Egetis debt, which adds significant borrowing and secured obligations for ANI shareholders.
Facility allows borrowings up to $676 million and matures 364 days after initial funding
Initial margin of 1.75% for ABR loans and 2.75% for adjusted term SOFR loans
Offer price is SEK 11.25 per Egetis share; total value about SEK 5.6 billion, or $559.9 million
Completion requires holders of at least 90% of Egetis shares (fully diluted) to tender and regulatory clearances; undertakings covering 42.2% of shares expire if the offer is not declared unconditional by March 31, 2027
ANI Pharmaceuticals reported third quarter 2026 net revenues of $290.8 million, up 27.6%, and GAAP diluted earnings per share of $1.51 versus $1.13 a year earlier. It cut its 2026 Cortrophin Gel revenue guidance to $480 million to $500 million from $520 million to $540 million, citing slower-than-expected conversion of demand into patients, while raising its adjusted EBITDA and adjusted EPS guidance, and it announced a recommended offer to acquire Egetis Therapeutics.
Q3 2026 Cortrophin Gel net revenues were $138.7 million, up 36.1%, while Brands revenue fell 6.5% to $10.0 million.
2026 Cortrophin Gel revenue guidance was revised to $480 million to $500 million, down from $520 million to $540 million; total company revenue guidance was narrowed to $1,085 million to $1,125 million.
Adjusted non-GAAP EBITDA guidance was raised to $290 million to $300 million, and adjusted non-GAAP diluted EPS guidance was raised to $9.37 to $9.71.
The Egetis offer is SEK 11.25 per share, valued at approximately $560 million including incentive programs; the acceptance period is expected to run from about November 20, 2026 to December 18, 2026.
ANI Pharmaceuticals appointed Henry Gosebruch, former AbbVie strategy chief and former Neumora CEO, as a director effective August 19, 2026. Director Muthusamy Shanmugam resigned from the board on August 23, 2026, but remains an executive as Head of R&D and Chief Operating Officer of New Jersey Operations. The filing describes Gosebruch's role as supporting business development and capital allocation, which is relevant to shareholders as the company pursues its Rare Disease transformation.
Henry Gosebruch, 53, appointed to the Board with a term expiring at the 2027 annual meeting
Initial restricted stock award with a grant date fair value of $525,000, vesting in three equal annual installments
Samy Shanmugam resigned as a director effective immediately on August 23, 2026, and stays in his executive role
ANI Pharmaceuticals reported second-quarter 2026 total net revenues of $266.0 million, up 25.9% from a year earlier, and GAAP net income available to common shareholders of $24.7 million, or $1.05 per diluted share, versus $0.36 in the prior-year quarter. The company reaffirmed its full-year total net revenue guidance of $1,080 million to $1,140 million and adjusted non-GAAP EBITDA guidance of $285 million to $300 million, but lowered its Cortrophin Gel net revenue guidance to $520 million to $540 million from $540 million to $575 million, which matters because Cortrophin Gel is the company's largest product.
Total net revenues were $266.0 million in Q2 2026, up from $211.4 million in Q2 2025.
Diluted GAAP EPS was $1.05 versus $0.36; adjusted non-GAAP diluted EPS was $2.21 versus $1.80.
Cortrophin Gel 2026 net revenue guidance was revised to $520 million to $540 million from $540 million to $575 million; total net revenue guidance of $1,080 million to $1,140 million was reaffirmed.
The board authorized a share repurchase program of up to $100.0 million in common stock through May 2029, effective May 8, 2026.
At its 2026 Annual Meeting on May 21, 2026, ANI Pharmaceuticals stockholders elected seven directors, ratified Ernst & Young LLP as the independent auditor for fiscal 2026, approved executive pay on an advisory basis, and approved the Amended and Restated 2022 Stock Incentive Plan. The company will hold advisory votes on executive pay every year, following the stockholders' frequency vote. The filing covers governance matters only and includes no financial results or guidance.
Amended 2022 Stock Incentive Plan approved: 13,806,050 for, 1,080,387 against, 9,388 abstain, 2,030,222 broker non-votes
Advisory say-on-pay proposal approved: 13,819,988 for and 1,058,460 against
Stockholders voted 14,412,299 for an annual advisory pay vote; the board will hold these votes every one year
Ernst & Young LLP ratified as auditor for fiscal year ending December 31, 2026: 16,874,103 for and 7,333 against
ANI Pharmaceuticals reported first quarter 2026 revenue of $237.5 million, up 20.5% from a year earlier, and GAAP net income of $29.5 million, or $1.28 per diluted share, compared with $0.69 a year earlier. The company raised its 2026 total net revenue, adjusted EBITDA and adjusted diluted EPS guidance and authorized a $100 million share repurchase program.
Q1 2026 total net revenues of $237.5 million, up 20.5%; Cortrophin Gel net revenues of $75.1 million, up 42.1%
GAAP diluted EPS of $1.28 vs. $0.69 a year earlier; adjusted non-GAAP diluted EPS of $2.05 vs. $1.70
2026 total net revenue guidance raised to $1,080 million to $1,140 million from $1,055 million to $1,115 million; adjusted non-GAAP EBITDA raised to $285 million to $300 million
Board authorized a $100 million share repurchase program effective May 8, 2026, running through May 2029; Brands net revenues fell 50.9%
ANI Pharmaceuticals reported record fourth-quarter and full-year 2025 results, with Q4 net revenue of $247.1 million and GAAP net income available to common shareholders of $27.5 million, compared with a loss in the prior-year quarter. The company reaffirmed its full-year 2026 guidance, including total net revenue of $1,055 million to $1,115 million, which matters to shareholders as a reaffirmation rather than a change in outlook.
Q4 2025 net revenue was $247.1 million, up 29.6%; Cortrophin Gel rose 87.6% to $111.4 million, while Brands fell 37.9% to $12.3 million
Q4 GAAP diluted EPS was $1.18 versus a loss of $0.55 a year earlier; adjusted non-GAAP diluted EPS was $2.33 versus $1.63
Full-year 2025 net revenue was $883.4 million, up 43.8%, with GAAP net income available to common shareholders of $77.2 million
2026 guidance reaffirmed: total net revenue $1,055 million to $1,115 million and adjusted non-GAAP diluted EPS $8.83 to $9.34
ANI Pharmaceuticals said preliminary, unaudited 2025 results are within or above its prior guidance, with Cortrophin Gel net revenues up 76% for the year. It also issued 2026 guidance calling for total net revenues of $1.055 billion to $1.115 billion and adjusted non-GAAP diluted EPS of $8.83 to $9.34, and said the 2025 figures may change materially before the audit is complete.
Preliminary 2025 total net revenues are expected to be within or above $854 million to $873 million, adjusted non-GAAP EBITDA $221 million to $228 million, and adjusted non-GAAP diluted EPS $7.37 to $7.64.
Cortrophin Gel net revenues were approximately $347.8 million for 2025, up 76% year over year, and approximately $111.4 million for the fourth quarter, up 88%.
2026 guidance: total net revenues $1.055 billion to $1.115 billion, adjusted non-GAAP EBITDA $275 million to $290 million, and adjusted non-GAAP diluted EPS $8.83 to $9.34.
The company had approximately $285 million in unrestricted cash and cash equivalents as of December 31, 2025; the company plans to report full 2025 results in late February.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ANI Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →